Objectives The common data elements (CDE) project was developed by the National Institute of Neurological Disorders and Stroke (NINDS) to provide clinical researchers with tools to improve data quality and allow for harmonization of data collected in different research studies. CDEs have been created for several neurological diseases; the aim of this project was to develop CDEs specifically curated for mitochondrial disease (Mito) to enhance clinical research.
Introduction
The Common Data Element (CDE) project began in 2005 as part of an initiative by the National Institute of Neurological Disorders and Stroke (NINDS) to assist NINDS-funded investigators in the collection of neuroscientific clinical trial research data in a standardized and consistent fashion (Grinnon et al 2012) . The CDEs are content standards that can be applied to various data collection models and are intended to be dynamic and evolve over time, as indicated by research advances. The CDE project is not a databaserather it is a collection of metadata and data standards, used to facilitate sharing and combination of data across studies as a means of data comparison and analysis. Its goal is to develop common definitions for clinical research data as well as the creation of standardized case report forms (CRFs) and instruments. The goals of the NINDS CDE Project are to: 1) Disseminate standards for data collection from participants enrolled in neurological disease studies; 2) Create easily accessible tools for investigators to collect study data. These tools should be especially helpful to new investigators and others working with limited budgets; 3) Encourage focused and simplified data collection to reduce burden on investigators and practice-based clinicians to facilitate their participation in clinical research; 4) Improve data quality while controlling cost by providing uniform data descriptions and tools across NINDS-funded clinical studies (Grinnon et al 2012) . As the CDEs were being developed, the number of clinical trials for patients with mitochondrial disease also rose, highlighting the value and urgency of such tools to be developed.
To date, the NINDS CDE database has developed metadata with data standards and instruments for 18 neurological diseases. In the case of mitochondrial disease, CDE validation can be complex due to the broad array of mechanisms causing mitochondrial diseases and dysfunction. This paper reviews the process by which the Mito WGs, an international group of mitochondrial disease experts, developed CDEs to be used in the field of mitochondrial disease research. The draft Mito CDEs were reviewed by the external mitochondrial disease research community prior to finalization and posted to the NINDS CDE website in 2015. The WG participant rosters may be found on the NINDS CDE web page (https:// commondataelements.ninds.nih.gov/).
Background Brief description of mitochondrial diseases
Mitochondrial diseases (also known as disorders of oxidative phosphorylation (OXPHOS), mitochondrial respiratory chain diseases, mitochondrial cytopathies, and mitochondriopathies) are a group of disorders caused by genetic defects that directly or indirectly affect the OXPHOS system, the major energy generating pathway in cells (Chinnery 2014; DiMauro and Schon 2003) . The prevalence of mitochondrial disease is difficult to establish for many reasons, including their clinical and genetic heterogeneity, challenges in establishing a precise genetic diagnosis, and complexities in patient ascertainment and referral. The prevalence of all pathogenic mutations in both nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) is at least 1:4300 (Gorman et al 2015) . Approximately 15% (DiMauro and Schon 2003) of mitochondrial disorders are caused by inherited germline mutations in the mtDNA. Mitochondrial disorders can also be caused by mutations in over 250 nDNA genes and dysfunction can be acquired due to adverse environmental effects of drugs and infections (Niyazov et al 2016) . Those disorders resulting from inherited nDNA or mtDNA gene mutations that have an effect on the structure or function of the OXPHOS system are termed Bprimary mitochondrial diseases ( Parikh et al 2015) . Some mitochondrial disorders affect a single organ, but many involve multiple organ systems and can present with a bewildering array of multisystem phenotypes, including neurologic symptoms and myopathies, visual and hearing loss, as well as cardiac, endocrine, gastrointestinal, hepatic, and/or renal dysfunction (Chinnery 2014) . Some well-characterized multisystem clinical syndromes have now been recognized as being mitochondrial diseases. Primary inherited mitochondrial diseases encompass hundreds of individual genetic disorders that are heterogeneous and frequently multisystemic, yet share common disease mechanisms and overlapping clinical phenotypes. One challenge, not necessarily unique to mitochondrial disorders, is that there may be great variation between individuals with the same mutation. With respect to mtDNA mutations (e.g., Mitochondrial encephalomyopathy, lactic acidosis and strokelike episodes (MELAS) mutation), variation may depend on the percentage heteroplasmy (mutation load) in any given tissue and the number of tissues harboring the mutation, adding to the wide phenotypic spectrum and variable disease severity. A comprehensive overview can be found on the North American Mitochondrial Disease Consortium (NAMDC) website (https:// www.rarediseasesnetwork.org/cms/namdc/Learn-More/ Disorder-Definitions).
Marked variability remains in the diagnostic approaches, treatment, and management of mitochondrial diseases (Parikh et al 2015) . Conducting large-scale clinical trials for patients with mitochondrial diseases is difficult, given their extreme clinical variability, biochemical and genetic heterogeneity, and the rarity of each etiology or subtype. Despite all of these constraints, several clinical trials for mitochondrial diseases are underway, none of which use any mitochondrial diseasespecific curated or validated outcome measure for this specific patient group.
Materials and methods
Developing CDEs for mitochondrial disorders was challenging due to the heterogeneity of potential disease symptoms that may develop. CDEs reviewed and selected for this project focused on features within and outside the domain of clinical neurology, spanning almost all organ systems. Selected CDEs would benefit the majority of individuals with mitochondrial disorders and would be linked to appropriate measures to objectively assess disease severity and progression. Therefore, the Mitochondrial Disease CDE WG was divided into nine subgroups to focus on identifying and defining data elements in the following domains: Biomarkers; Cognitive/Behavioral/ Psychological; Endocrinology/Diabetes/Gastrointestinal/ Nutrition; Exercise Physiology; Genetics; Imaging; Neurological Assessments; Patient Reported Outcomes/ Quality of Life; and Vision. Bi-weekly teleconferences for each WG for a period of six months were held until project completion. In order to remain consistent with the overall CDE format, the WG recommendations were classified into one of four categories:
Core: A data element for recording essential information applicable to any mitochondrial disease study including therapeutic areas and study designs. Consistent with all NINDS disease-specific CDE sets, the Core Mito CDEs are a small subset of all available CDEs that are the most specific and valuable for all Mito studies. Supplemental-highly recommended: A data element which is recommended for use whenever applicable, based on certain conditions or clinical study designs. In most cases, these have been used and validated with strong psychometrics for use in mitochondrial disease, and are considered essential for clinical research studies by experts in the field. Supplemental: A data element which has some evidence of validity and is commonly collected in clinical studies in mitochondrial disease. Use depends upon the study design, protocol or type of research involved. Exploratory: A data element that could be emerging or that requires further validation in target populations, but may fill current gaps in the CDEs and/or substitute for an existing CDE with additional evidence.
Pre-existing individual CDEs selected for other clinically similar disease phenotypes were included and other appropriate instruments were added when available. All were critically evaluated for appropriateness to mitochondrial disorders even if historical reliability and validity was accepted for other diseases. Statistical analysis was not performed at this time, as this is not applicable for the development and initial description of the Mito CDEs. In the future, statistical analyses will help determine if these CDEs can be specifically validated for mitochondrial diseases. The draft Mito CDEs were posted on the NINDS CDE website for public review from November 20, 2014 to January 16, 2015. The final Version 1.0 Mito CDEs were posted on February 25, 2015, following the incorporation of comments received from public review from the mitochondrial clinical research community. The process describing the formation of the CDEs is available on the CDE website at https://www.commondataelements.ninds.nih.gov/ CDEStandard.aspx.F i g u r e1 illustrates the mitochondrial CDE development process. Core elements for the mitochondrial disorders included one general core element common to all other disorders reviewed for CDEs, namely the demographic patient/participant characteristics. The WGs did not find any element that was strongly representative of mitochondrial disorders, and thus no additional core elements specifically required for all mitochondrial disorders were selected. Of the remaining recommended categories, 17% of the elements assessed were categorized as supplemental-highly recommended, 75% as supplemental, and 8% as exploratory. The Highlight Summary Document is available in table format on the CDE webpage (https:// www.commondataelements.ninds.nih.gov/Doc/MITO/ Mitochondrial_Disease_CDE_Highlight_Summary.pdf). There were no core elements recommended due to lack of validation in mitochondrial disease cohorts. The Supplemental-highly recommended instruments (for specific disease conditions or types of study) included: Anthropometrics-Vital Signs, Apathy Evaluation Scale, Automated Self-administered 24-hour Dietary Recall (ASA 24), Barry Albright Dystonia Scale (BADS), Behavior 
WG results summary Biomarkers
The Mito Biomarkers WG found that none of the reported biomarkers are consistently altered, nor have been used to assess mitochondrial disease in every study. For example, elevated lactic acid, commonly considered to be a biomarker of mitochondrial disease, is not consistently elevated in blood across all mitochondrial diseases, especially when only a single organ is involved (e.g., the eye in Leber'shereditaryoptic neuropathy). Conversely, lactate levels in bold are frequently elevated in many pediatric mitochondrial diseases where the oxidative phosphorylation deficiency is often both severe and widespread. The WG also considered some parameters that are absolutely essential, but in only one disease. For example, thymidine and deoxyuridine levels along with thymidine phosphorylase enzymology are only useful in Mitochondrial neurogastrointestinal encephalopathy (MNGIE) syndrome, a very rare genetic disease caused by thymidine phosphorylase deficiency. The WG found the task of defining an extensive list of Bspecific^parameters difficult because of the high, and steadily increasing, number of different causes of mitochondrial diseases as well as a growing list of new biomarkers (e.g. FGF-21, GDF-15) (Suomalainen 2013; Yatsuga et al 2015) . As a result, all biomarkers recommended by the WG are classified as Supplemental and were fully defined in a guidelines document to assist researchers in their studies. Cognitive/behavioral/psychological outcomes A broad range of clinical phenotypes is observed in both children and adults with mitochondrial disorders, with symptoms that may progressively develop and wax and wane in severity over the course of the entire lifespan. As a result, the instruments recommended vary according to age and the specific type of disorder. Furthermore, the scoring and use of the instruments may vary based on the clinical history. Modification of the scoring system for some of the instruments may be recommended to achieve higher sensitivity of symptom assessment (i.e., use of raw scores vs. standard scores). The WG also suggested considering the intended use of the instrument in any given study, such as a natural history to study changes over time in a clinical trial. The WG recommends selecting individual components of the larger tools to study in clinical trials. An example of this would be the use of memory or executive functioning subsets of the NIH Toolbox instead of using the whole instrument. While choosing instrument recommendations, the group did not encounter any tools unique to individuals with mitochondrial disorders and therefore there are no validated tools available for this population of patients.
Endocrinology/diabetes/gastrointestinal/nutrition
Diabetes mellitus, abnormal growth, gastrointestinal (GI) problems and nutrition-related concerns are important features of mitochondrial disease. This WG developed instruments focused on diabetes mellitus, anthropometric measurements, GI symptoms and nutritional assessment, including diet and use of dietary supplements. The WG acknowledged that the diversity of current approaches to treatment of mitochondrial disease in general and particular subtypes in particular, including nutrition and supplements, leads to difficulties in standardized documentation to enable ready evaluation of their potential impact. Given their importance to the overall health of affected individuals, careful assessment and study of endocrine and GI-related health conditions was recommended. The Office of Dietary Supplements at NIH organized a community meeting and subsequent working group dedicated to further investigation of the impact of nutritional interventions in primary mitochondrial diseases (Camp et al 2016) .
Exercise physiology
The exercise physiology WG focused on the areas of exercise intolerance, endurance, and exercise recommendations. Exercise intolerance is one of the most prevalent symptoms of mitochondrial disease, especially in adults with mitochondrial myopathy. The WG did not address clinical recommendations on exercise as a treatment, but rather focused on recommended instruments to measure fatigue, exercise intolerance, and ability to exercise. The Borg Scale of Perceived Exertion, The Newcastle Pediatric Mitochondrial Disease Scale (NPMDS), echocardiogram, electrocardiogram, maximum and submaximum exercise testing, and pulmonary function testing were recommended as supplemental-highly recommended tests. The 6-minute walk test is widely used in clinical trials as a reflection of overall exercise capacity, and was considered to be a Supplemental test for mitochondrial disease evaluation as determined by evidence available to the exercise physiology WG.
Genetics
Inclusion in clinical trials increasingly requires the establishment of a known pathogenic mutation in a mitochondrial disease-associated gene using standard criteria. Thus, establishing an accurate molecular diagnosis is important for clinical trial participation. The genetics WG made a clear distinction between genetic testing for clinical purposes (i.e., in a CLIA-certified diagnostic laboratory) versus on a research basis. Genetic testing should be performed in an experienced laboratory with clearly defined analytic methodology. Depending on clinical presentation and exact methodology used, such analyses may include next generation sequencing of relevant nuclear genes in the form of gene panels and/or the exome, genome-wide SNP microarray analysis to detect nuclear chromosomal copy number alterations, and mitochondrial genome next generation sequencing to detect low level heteroplasmy for mitochondrial point mutations or small copy number alterations, real-time quantitative PCR to detect large mtDNA deletions and duplications, and/or quantitative PCR to measure mtDNA genome content in relevant tissues. The specific DNA variant identified should be documented relative to a reference sequence and using established ACMG guidelines (Richards et al 2015) . If available, previous publications reporting pathogenicity of the variant should be cited (MacArthur et al 2014) .
Often this is performed through literature or database searches, using online tools such as MITOMAP (Lott et al 2013) and ClinVar (Harrison et al 2016) . If the variant is novel, and prediction programs such as PolyPhen and SIFT are used, the specific versions and tools should be cited because, occasionally, multiple programs may issue conflicting predictions. Segregation studies within the family should be performed to confirm expected inheritance patterns. Biochemical studies should be performed in subjects' blood, urine, cells, and/or tissue to confirm mitochondrial dysfunction type and degree, as needed or appropriate. In certain instances, in vitro cellular and/or animal model experiments might be needed to further evaluate the pathogenicity of novel variants of unknown significance.
Imaging
The imaging WG aimed to establish a data form that would be all-inclusive, ideally serving as a reference guide for what imaging data points might be useful to collect when researching mitochondrial disorders. While recommending many existing imaging CDEs, the WG highlighted several variables in the Mito imaging CRF that are characteristic of, although not exclusive, to mitochondrial disorders. The most notable elements are the involvement of deep gray nuclei, white matter tracts, and myelination pattern.
Neurological assessments
The spectrum of clinical manifestations of mitochondrial diseases spans every component of the nervous system (i.e., brain, spinal cord, peripheral nerves, autonomic nervous system, and muscle). The scales to capture a specific neurological disability vary in regard to their universal acceptance, sensitivity, complexity, and time-for-completion. As the CDEs are a project of the NINDS, and several other neurological diseases already had completed CDEs available for review, the Mito CDE WGs had the benefit of reviewing CDEs for clinically overlapping disorders including: Friedreich ataxia, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, Duchenne muscular dystrophy, stroke, spinal cord injury, and Huntington and Parkinson diseases. As many of the progressive neurological disorders have overlapping clinical symptoms, as well as secondary mitochondrial dysfunction contributing to their pathophysiology, many of the CRFs from these other neurological diseases were potentially applicable as Mito CDEs. The WG recommended that the choice of scales for a specific patient or study should include those that best measure function for the identified disability, and possibly scales that would measure function from the pre-symptomatic state for expected disabilities that could be predicted to develop by the patient's clinical diagnosis or genotype. The WG aimed to provide a battery of neurological tests that would capture small changes in cognitive function, development, motor weakness (muscle and nerve), coordination, and movement disorders (e.g., ataxia, dystonia).
Patient reported outcomes/quality of life (PRO/QoL)
The PRO/QoL WG found no QoL CDEs to be essential, and thus no instruments were classified as core. The recommended instruments had no differential application to subtypes of mitochondrial disease. However, the scales are often dependent on subject age for administration, and some are better suited for subjects with higher cognitive skills. Among several available QoL scales, the WG determined two that should be supplemental-highly recommended: the World Health Organization Quality of Life Assessment (WHOQOL) and the Pediatric Quality of Life Inventory (PEDSQL). Due to overall limitations, lack of a validated instrument, and the heterogeneity of mitochondrial diseases, it was difficult to define universal CDEs for QoL within mitochondrial diseases.
Vision
The vision WG recommendations were made to be applicable to all types of mitochondrial disease. Adequate training of physicians and technicians performing various ophthalmological tests with ongoing quality control were deemed essential. Several platforms were identified that are available for visual field perimetry and optical coherence tomography (OCT) imaging. The chosen tests will largely depend on the preference of the investigators and the specific facilities available in their respective study centers. The WG emphasized the need to ensure that the same platform and acquisition protocol are used across all the centers involved in a given study to allow for direct comparison and/or grouping of data at study conclusion. For visual electrophysiology, it was deemed imperative that testing be performed to incorporate the International Society for Clinical Electrophysiology of Vision (ISCEV) standards.
Discussion
The development of CDEs to facilitate mitochondrial disease research is timely, in view of the improvements and implementation of widespread genetic testing that has led to genetically-defined mitochondrial diseases and large patient cohorts. In addition, there has been a recent increase in candidate therapies proposed for these currently incurable disorders, with promising results in several preclinical studies in cell and animal models (Rahman 2015; Nightingale et al 2016) . The CDE project is an international collaborative effort involving the many key stakeholders in mitochondrial medicine, including clinicians, translational and basic researchers, industry partners, patient advocacy groups, and the NIH. The breadth of our collaborators is a testament to the interest and need for these shared research tools to move the mitochondrial medicine field forward.
The WGs reviewed a total of 153 CRFs and instruments for the possible inclusion in the Mito CDEs. Interestingly, and perhaps not surprisingly, the WGs did not find a single core data element; demonstrating once again the challenges for clinical research in mitochondrial diseases.
The CDEs were categorized based on their prior use in both mitochondrial diseases or similar disorders and whether they were scientifically robust and clinically significant. Together, these CDEs cover almost the entire disease spectrum of these complex multi-systemic disorders, and have been developed with the intention of providing a publicly available resource to facilitate the design of protocols for any clinical study relating to mitochondrial disease. Some caveats should be noted. The Mito CDEs are suggested guidelines rather than definitive requirements for future study protocols and are not intended for use in clinical patient care. Clinical study design should take into account the specific diseases (considering both genotype and phenotype) under study, age group of affected patients and nature of the intervention, and incorporate the most relevant CDEs, in addition to any other outcome measures that the researchers consider appropriate. The Mito CDE recommendations are based on current knowledge of a rapidly expanding and changing group of heterogeneous disorders, and it is anticipated that, while having a stable set of essential elements, these will be dynamic and need to be updated as the field advances and specific instruments become validated for use in mitochondrial disease. The NINDS has developed oversight committees that will review feedback from the community and adjust the CDEs periodically, as needed.
The availability of a global set of CDEs addressing many of the multi-systemic features should help serve as a starting place to harmonize data collection and ultimately enable the combination and comparison of outcomes of clinical studies in mitochondrial diseases. Given the diversity and spectrum of clinical manifestations seen in these disorders, selection of outcome measures for clinical research presents a unique challenge. These difficulties are further compounded by the rarity of each individual genetic entity of this group of disorders, challenges to robust study design, and need for substantive funding. It is thus imperative that patient support groups, together with mitochondrial disease clinician networks and research consortia, partner with industry and the FDA to validate these measures, recently discussed at a Critical Path Innovation Meeting (CPIM) (https://ods.od.nih.gov/ attachments/CriticalPathInnovationMeetingSummary.pdf). The international collaboration on this CDE project has continued to be fruitful, with projects ongoing to harmonize global patient registries, to validate patient-centered outcome measures, and to create mitochondrial disease specific outcome measures inspired by the CDEs reviewed in this project.
